Cadrenal Therapeutics (NASDAQ:CVKD) Stock Price Expected to Rise, HC Wainwright Analyst Says

Cadrenal Therapeutics (NASDAQ:CVKD) had its price target lifted by HC Wainwright from $3.00 to $32.00 in a research note published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Cadrenal Therapeutics Trading Up 0.1 %

Shares of NASDAQ:CVKD opened at $17.90 on Monday. The company’s 50-day moving average price is $13.09. The company has a market capitalization of $19.12 million, a P/E ratio of -2.68 and a beta of 1.52. Cadrenal Therapeutics has a 12 month low of $5.40 and a 12 month high of $32.55.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.